Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

References

1. Fifty Years of X-ray Diffraction, P.P. Ewald, Ed. (A. Oosthoek's Uitgeversmaatschappij, Utrecht, 1962).

2. M. Lambert, Acta Crystallogr. 57 (1), 1–3 (2001).

3. J. Schurz, Colloid Polym. Sci. 273 (10), 994–995 (1995).

4. Small Angle X-ray Scattering, O. Glatter and O. Kratky, Eds. (Academic Press, London, 1982) 4f.

5. H. Schnablegger and Y. Singh, "A Practical Guide to SAXS," (Anton Paar, Graz, Austria, 2006).

6. J. Lake, Acta Crystallogr. 23 (2), 191 (1967).

7. G.R. Strobl, Acta Crystallogr. A 26 (3), 367–375 (1970).

8. M. Soliman, B.J. Jungnickel, and E. Meister, Acta Crystallogr., A, Found. 54 (5), 675–681 (1998).

9. C. Jeffries et al., J. Mol. Biol. 377 (4), 1186–1199 (2008).

10. H. Schnablegger, "Is Smearing An Issue?" (Anton Paar Graz, Austria, 2007).

11. M. Muthukumar, C.K. Ober, and E.L. Thomas, Science 277 (5330), 1225–1232 (1997).

12. G.M. Whitesides, J.P. Mathias, and C.T. Seto, Science 254 (5036), 1312–1319 (1991).

13. G.M. Whitesides and B. Crzybowski, Science 295 (5552), 2418–2421 (2002).

14. A.M. Edwards et al., Nat. Struct. Biol. 7 (11), 970–972 (2000).

15. R.F. Fischetti et al., J. Synchrotron Radiat. 10 (5), 398–404 (2003).

16. M. Hirai et al., J. Synchrotron Radiat. 9 (4), 202–205 (2002).

17. D.M. Tiede, R. Zhang, and S. Seifert, Biochemistry 41, 6605–6614 (2002).

18. R. Zhang, P. Thiyagarajan, and D.M. Tiede, J. Appl. Crystallogr. 33 (3), 565–568 (2000).

19. D.I. Svergun and M.H.J. Koch, Rep. Prog. Phys. 66 (10), 1735–1782 (2003).

20. J. Trewhella and J.K. Krueger, Methods Mol. Biol. 173, 137–159 (2002).

21. P. Chacon et al., Biophys. J. 74 (6), 2760–2775 (1998).

22. P. Chacon et al., J. Mol. Biol. 299 (5), 1289–1302 (2000).

23. D. Svergun, Biophys. J. 76 (6), 2879–2886 (1999), erratum in 77, (5), 2896–2896 (1999).

24. G. Fritz, A. Bergmann, and O. Glatter, J. Chem. Phys. 113 (21), 9733–9740 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here